Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics, Definiens Expand Biomarker Alliance

NEW YORK (GenomeWeb) – NeoGenomics and Definiens announced today that they have expanded their cancer biomarker discovery alliance to include the development and automation of assays for clinical trials and clinical testing.

Under the terms of the new deal, Definiens will provide automated quantitative biomarker solutions to support NeoGenomics’ immunohistochemistry services for both its pharma services customers and clinical clients to help improve pathology interpretation, standardize readouts, and identify signatures for optimal biomarker cut point thresholds.

Additional terms were not disclosed.

In 2008, Definiens partnered with Clarient to codevelop biomarker image analysis tools for Clarient to use in its internal research programs and offer its customers.

In late 2015, NeoGenomics bought Clarient for a combination of cash and stock.

"Our relationship with Definiens has allowed us to further automate some of our important immunohistochemistry services for clinical trials and for clinical testing, and we are looking forward to leveraging this relationship further," NeoGenomics Chairman and CEO Douglas VanOort said in a statement.

In a note to investors, Cantor Fitzgerald analyst Bryan Brokmeier said that the expanded alliance with Definiens is expected to further enhance and differentiate NeoGenomics' immunohistochemistry offerings, allowing it to better compete with larger contract research organizations.